-+ 0.00%
-+ 0.00%
-+ 0.00%

Altimmune prices oversubscribed USD 225 million public offering with warrants

PUBT·04/23/2026 03:25:19
Listen to the news
Altimmune prices oversubscribed USD 225 million public offering with warrants
  • Altimmune priced an underwritten public offering expected to raise about USD 225 million in gross proceeds.
  • Deal includes 64,250,000 common shares sold with accompanying common stock warrants at a combined price of USD 3 per share.
  • Offering also includes up to 10,750,000 pre-funded warrants with accompanying common stock warrants at a combined price of USD 2.999.
  • Accompanying common stock warrants carry an exercise price of USD 3 per share with expiry tied to a Phase 3 pemvidutide MASH data readout or five years.
  • Net proceeds earmarked to fund upcoming Phase 3 trial in MASH, working capital, general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604222325PRIMZONEFULLFEED9695566) on April 23, 2026, and is solely responsible for the information contained therein.